Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Alex Azar, President Trump's nominee to lead HHS. Photo: Bill Clark/CQ Roll Call, via Getty Images

Senate Democrats are pressing Alex Azar on the cost of prescription drugs, as the Finance Committee weighs his nomination for Health and Human Services secretary. Sen. Ron Wyden, the committee’s top Democrat, noted that several Eli Lilly drugs saw steep price hikes while Azar ran the company, and asked whether he had ever lowered the price of a product.

“I don’t know that there is any drug price, of a branded product, that has ever gone down — from any company, on any drug, in the United States, because every incentive in this system is toward higher prices,” Azar said, arguing that he could help reshape that system because he knows it well.
  • Value-based contracting — in which drug companies are paid based on how well their products work — “can be vitally important, Azar said, but Medicare’s regulations can “get in the way.”
  • Asked about President Trump's past support for allowing Medicare to negotiate what it will pay for drugs, Azar said the program's prescription drug benefit already has sufficient bargaining tools. But he said he would be open to "looking at" extending those practices into the part of Medicare that covers drugs administered in a doctor's office.

Go deeper

1 hour ago - Health

Beware a Thanksgiving mirage

Illustration: Sarah Grillo/Axios

Don't be surprised if COVID metrics plunge over the next few days, only to spike next week.

Why it matters: The COVID Tracking Project warns of a "double-weekend pattern" on Thanksgiving — where the usual weekend backlog of data is tacked on to a holiday.

Trump pardons Michael Flynn

President Trump with Michael Flynn in 2016. Photo: David Hume Kennerly/Getty Images

President Trump on Wednesday pardoned his former national security adviser Michael Flynn, who pleaded guilty in the Mueller investigation to lying to FBI agents about his conversations with a former Russian ambassador.

Why it matters: It is the first of multiple pardons expected in the coming weeks, as Axios scooped Tuesday night.